Final press release
Icosagen–EPOK EPRA-0322 Press Release
↓ Download
Search from website
Search from website
Download the press release, company logos, spokesperson photographs and editorial images related to Icosagen's development of a manufacturing-ready CHO cell line for EPOK Therapeutics' EPRA-0322 program.
For additional materials, image permissions, interview coordination, technical follow-up or administrative questions related to this announcement, please contact Karl Mumm, Marketing Manager at Icosagen.
Background information on the cell line development platform, GMP manufacturing capabilities and therapeutic program featured in this announcement.
Explore Icosagen's proprietary platform for stable, high-producing CHO cell lines designed for scalable clinical and commercial GMP manufacturing.
Explore cell line development →Learn how Icosagen connects cell line development, process development, analytical characterization and clinical GMP manufacturing within one integrated CRDMO.
Explore GMP manufacturing →Learn more about EPOK Therapeutics and its development of innovative therapeutic proteins for metabolic diseases, including its lead program for anemia related to chronic kidney disease.
Visit EPOK Therapeutics →Discover Icosagen's integrated CRDMO capabilities from antibody discovery and protein engineering through developability, CHO cell line development and clinical GMP manufacturing.
Visit Icosagen →Let's get you there!
© 2026 Icosagen
